Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial
Beller, E. ; Tattersall, M. ; Lumley, T. ; Levi, J. ; Dalley, D. ; Olver, I. ; Page, J. ; Abdi, E. ; Wynne, C. ; Friedlander, M. ; Boadle, D. ; Wheeler, H. ; Margrie, S. ; Simes, R. J.
Springer
Published 1997
Springer
Published 1997
| ISSN: |
1569-8041
|
|---|---|
| Keywords: |
cachexia ; megestrol acetate ; quality of life
|
| Source: |
Springer Online Journal Archives 1860-2000
|
| Topics: |
Medicine
|
| Notes: |
Abstract Purpose: To investigate the effect of two doses of megestrol acetate(MA) compared with placebo on quality of life (QoL) and nutritional status(NS) in patients with advanced endocrine-insensitive cancer. Patients and methods: Two hundred forty patients were randomised todouble-blind MA 480 mg/day, MA 160 mg/day, or matching placebo for 12 weeks.Nutritional status (including weight, skinfold thickness and midarmcircumference) and QoL (using 6 linear analogue self-assessment (LASA) scales)were assessed at randomisation and after four, eight and 12 weeks. A QoLranking incorporating QoL and death was also used ranging from 1 = dead to 5= much better QoL. Results: One hundred seventy-four patients were assessable at weekfour, 136 at week eight and 103 patients at week 12. Patients receiving MAreported substantially better appetite (P = 0.001), mood (P =0.001) and overall quality of life ( P 〈 0.001), and possibly lessnausea and vomiting (P = 0.08) than patients receiving placebo, basedon a test for trend. A larger benefit was seen with the higher dose which(unlike the lower dose) was significantly better in pairwise comparisons withplacebo for appetite, mood and overall QoL (each P≤ 0.001). Despitesome missing data on QoL scores, QoL ranking was available on 227 (95%)of patients with significantly higher QoL ranking associated with MA (P= 0.002). Improvements in QoL occurred early within four weeks and weresustained. No statistically significant differences were observed in NSmeasurements, including weight (P = 0.29). Side effects of therapy wereminor and did not differ significantly across treatments. Conclusion: Megestrol acetate given at 480 mg/day is usefulpalliation in patients with endocrine-insensitive advanced cancer. It improvesappetite, mood and overall quality of life in these patients, although notthrough a direct effect on nutritional status.
|
| Type of Medium: |
Electronic Resource
|
| URL: |
| _version_ | 1798296353972944896 |
|---|---|
| autor | Beller, E. Tattersall, M. Lumley, T. Levi, J. Dalley, D. Olver, I. Page, J. Abdi, E. Wynne, C. Friedlander, M. Boadle, D. Wheeler, H. Margrie, S. Simes, R. J. |
| autorsonst | Beller, E. Tattersall, M. Lumley, T. Levi, J. Dalley, D. Olver, I. Page, J. Abdi, E. Wynne, C. Friedlander, M. Boadle, D. Wheeler, H. Margrie, S. Simes, R. J. |
| book_url | http://dx.doi.org/10.1023/A:1008291825695 |
| datenlieferant | nat_lic_papers |
| hauptsatz | hsatz_simple |
| identnr | NLM192898469 |
| issn | 1569-8041 |
| journal_name | Annals of oncology |
| materialart | 1 |
| notes | Abstract Purpose: To investigate the effect of two doses of megestrol acetate(MA) compared with placebo on quality of life (QoL) and nutritional status(NS) in patients with advanced endocrine-insensitive cancer. Patients and methods: Two hundred forty patients were randomised todouble-blind MA 480 mg/day, MA 160 mg/day, or matching placebo for 12 weeks.Nutritional status (including weight, skinfold thickness and midarmcircumference) and QoL (using 6 linear analogue self-assessment (LASA) scales)were assessed at randomisation and after four, eight and 12 weeks. A QoLranking incorporating QoL and death was also used ranging from 1 = dead to 5= much better QoL. Results: One hundred seventy-four patients were assessable at weekfour, 136 at week eight and 103 patients at week 12. Patients receiving MAreported substantially better appetite (P = 0.001), mood (P =0.001) and overall quality of life ( P 〈 0.001), and possibly lessnausea and vomiting (P = 0.08) than patients receiving placebo, basedon a test for trend. A larger benefit was seen with the higher dose which(unlike the lower dose) was significantly better in pairwise comparisons withplacebo for appetite, mood and overall QoL (each P≤ 0.001). Despitesome missing data on QoL scores, QoL ranking was available on 227 (95%)of patients with significantly higher QoL ranking associated with MA (P= 0.002). Improvements in QoL occurred early within four weeks and weresustained. No statistically significant differences were observed in NSmeasurements, including weight (P = 0.29). Side effects of therapy wereminor and did not differ significantly across treatments. Conclusion: Megestrol acetate given at 480 mg/day is usefulpalliation in patients with endocrine-insensitive advanced cancer. It improvesappetite, mood and overall quality of life in these patients, although notthrough a direct effect on nutritional status. |
| package_name | Springer |
| publikationsjahr_anzeige | 1997 |
| publikationsjahr_facette | 1997 |
| publikationsjahr_intervall | 8004:1995-1999 |
| publikationsjahr_sort | 1997 |
| publisher | Springer |
| reference | 8 (1997), S. 277-283 |
| schlagwort | cachexia megestrol acetate quality of life |
| search_space | articles |
| shingle_author_1 | Beller, E. Tattersall, M. Lumley, T. Levi, J. Dalley, D. Olver, I. Page, J. Abdi, E. Wynne, C. Friedlander, M. Boadle, D. Wheeler, H. Margrie, S. Simes, R. J. |
| shingle_author_2 | Beller, E. Tattersall, M. Lumley, T. Levi, J. Dalley, D. Olver, I. Page, J. Abdi, E. Wynne, C. Friedlander, M. Boadle, D. Wheeler, H. Margrie, S. Simes, R. J. |
| shingle_author_3 | Beller, E. Tattersall, M. Lumley, T. Levi, J. Dalley, D. Olver, I. Page, J. Abdi, E. Wynne, C. Friedlander, M. Boadle, D. Wheeler, H. Margrie, S. Simes, R. J. |
| shingle_author_4 | Beller, E. Tattersall, M. Lumley, T. Levi, J. Dalley, D. Olver, I. Page, J. Abdi, E. Wynne, C. Friedlander, M. Boadle, D. Wheeler, H. Margrie, S. Simes, R. J. |
| shingle_catch_all_1 | Beller, E. Tattersall, M. Lumley, T. Levi, J. Dalley, D. Olver, I. Page, J. Abdi, E. Wynne, C. Friedlander, M. Boadle, D. Wheeler, H. Margrie, S. Simes, R. J. Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial cachexia megestrol acetate quality of life cachexia megestrol acetate quality of life Abstract Purpose: To investigate the effect of two doses of megestrol acetate(MA) compared with placebo on quality of life (QoL) and nutritional status(NS) in patients with advanced endocrine-insensitive cancer. Patients and methods: Two hundred forty patients were randomised todouble-blind MA 480 mg/day, MA 160 mg/day, or matching placebo for 12 weeks.Nutritional status (including weight, skinfold thickness and midarmcircumference) and QoL (using 6 linear analogue self-assessment (LASA) scales)were assessed at randomisation and after four, eight and 12 weeks. A QoLranking incorporating QoL and death was also used ranging from 1 = dead to 5= much better QoL. Results: One hundred seventy-four patients were assessable at weekfour, 136 at week eight and 103 patients at week 12. Patients receiving MAreported substantially better appetite (P = 0.001), mood (P =0.001) and overall quality of life ( P 〈 0.001), and possibly lessnausea and vomiting (P = 0.08) than patients receiving placebo, basedon a test for trend. A larger benefit was seen with the higher dose which(unlike the lower dose) was significantly better in pairwise comparisons withplacebo for appetite, mood and overall QoL (each P≤ 0.001). Despitesome missing data on QoL scores, QoL ranking was available on 227 (95%)of patients with significantly higher QoL ranking associated with MA (P= 0.002). Improvements in QoL occurred early within four weeks and weresustained. No statistically significant differences were observed in NSmeasurements, including weight (P = 0.29). Side effects of therapy wereminor and did not differ significantly across treatments. Conclusion: Megestrol acetate given at 480 mg/day is usefulpalliation in patients with endocrine-insensitive advanced cancer. It improvesappetite, mood and overall quality of life in these patients, although notthrough a direct effect on nutritional status. 1569-8041 15698041 Springer |
| shingle_catch_all_2 | Beller, E. Tattersall, M. Lumley, T. Levi, J. Dalley, D. Olver, I. Page, J. Abdi, E. Wynne, C. Friedlander, M. Boadle, D. Wheeler, H. Margrie, S. Simes, R. J. Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial cachexia megestrol acetate quality of life cachexia megestrol acetate quality of life Abstract Purpose: To investigate the effect of two doses of megestrol acetate(MA) compared with placebo on quality of life (QoL) and nutritional status(NS) in patients with advanced endocrine-insensitive cancer. Patients and methods: Two hundred forty patients were randomised todouble-blind MA 480 mg/day, MA 160 mg/day, or matching placebo for 12 weeks.Nutritional status (including weight, skinfold thickness and midarmcircumference) and QoL (using 6 linear analogue self-assessment (LASA) scales)were assessed at randomisation and after four, eight and 12 weeks. A QoLranking incorporating QoL and death was also used ranging from 1 = dead to 5= much better QoL. Results: One hundred seventy-four patients were assessable at weekfour, 136 at week eight and 103 patients at week 12. Patients receiving MAreported substantially better appetite (P = 0.001), mood (P =0.001) and overall quality of life ( P 〈 0.001), and possibly lessnausea and vomiting (P = 0.08) than patients receiving placebo, basedon a test for trend. A larger benefit was seen with the higher dose which(unlike the lower dose) was significantly better in pairwise comparisons withplacebo for appetite, mood and overall QoL (each P≤ 0.001). Despitesome missing data on QoL scores, QoL ranking was available on 227 (95%)of patients with significantly higher QoL ranking associated with MA (P= 0.002). Improvements in QoL occurred early within four weeks and weresustained. No statistically significant differences were observed in NSmeasurements, including weight (P = 0.29). Side effects of therapy wereminor and did not differ significantly across treatments. Conclusion: Megestrol acetate given at 480 mg/day is usefulpalliation in patients with endocrine-insensitive advanced cancer. It improvesappetite, mood and overall quality of life in these patients, although notthrough a direct effect on nutritional status. 1569-8041 15698041 Springer |
| shingle_catch_all_3 | Beller, E. Tattersall, M. Lumley, T. Levi, J. Dalley, D. Olver, I. Page, J. Abdi, E. Wynne, C. Friedlander, M. Boadle, D. Wheeler, H. Margrie, S. Simes, R. J. Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial cachexia megestrol acetate quality of life cachexia megestrol acetate quality of life Abstract Purpose: To investigate the effect of two doses of megestrol acetate(MA) compared with placebo on quality of life (QoL) and nutritional status(NS) in patients with advanced endocrine-insensitive cancer. Patients and methods: Two hundred forty patients were randomised todouble-blind MA 480 mg/day, MA 160 mg/day, or matching placebo for 12 weeks.Nutritional status (including weight, skinfold thickness and midarmcircumference) and QoL (using 6 linear analogue self-assessment (LASA) scales)were assessed at randomisation and after four, eight and 12 weeks. A QoLranking incorporating QoL and death was also used ranging from 1 = dead to 5= much better QoL. Results: One hundred seventy-four patients were assessable at weekfour, 136 at week eight and 103 patients at week 12. Patients receiving MAreported substantially better appetite (P = 0.001), mood (P =0.001) and overall quality of life ( P 〈 0.001), and possibly lessnausea and vomiting (P = 0.08) than patients receiving placebo, basedon a test for trend. A larger benefit was seen with the higher dose which(unlike the lower dose) was significantly better in pairwise comparisons withplacebo for appetite, mood and overall QoL (each P≤ 0.001). Despitesome missing data on QoL scores, QoL ranking was available on 227 (95%)of patients with significantly higher QoL ranking associated with MA (P= 0.002). Improvements in QoL occurred early within four weeks and weresustained. No statistically significant differences were observed in NSmeasurements, including weight (P = 0.29). Side effects of therapy wereminor and did not differ significantly across treatments. Conclusion: Megestrol acetate given at 480 mg/day is usefulpalliation in patients with endocrine-insensitive advanced cancer. It improvesappetite, mood and overall quality of life in these patients, although notthrough a direct effect on nutritional status. 1569-8041 15698041 Springer |
| shingle_catch_all_4 | Beller, E. Tattersall, M. Lumley, T. Levi, J. Dalley, D. Olver, I. Page, J. Abdi, E. Wynne, C. Friedlander, M. Boadle, D. Wheeler, H. Margrie, S. Simes, R. J. Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial cachexia megestrol acetate quality of life cachexia megestrol acetate quality of life Abstract Purpose: To investigate the effect of two doses of megestrol acetate(MA) compared with placebo on quality of life (QoL) and nutritional status(NS) in patients with advanced endocrine-insensitive cancer. Patients and methods: Two hundred forty patients were randomised todouble-blind MA 480 mg/day, MA 160 mg/day, or matching placebo for 12 weeks.Nutritional status (including weight, skinfold thickness and midarmcircumference) and QoL (using 6 linear analogue self-assessment (LASA) scales)were assessed at randomisation and after four, eight and 12 weeks. A QoLranking incorporating QoL and death was also used ranging from 1 = dead to 5= much better QoL. Results: One hundred seventy-four patients were assessable at weekfour, 136 at week eight and 103 patients at week 12. Patients receiving MAreported substantially better appetite (P = 0.001), mood (P =0.001) and overall quality of life ( P 〈 0.001), and possibly lessnausea and vomiting (P = 0.08) than patients receiving placebo, basedon a test for trend. A larger benefit was seen with the higher dose which(unlike the lower dose) was significantly better in pairwise comparisons withplacebo for appetite, mood and overall QoL (each P≤ 0.001). Despitesome missing data on QoL scores, QoL ranking was available on 227 (95%)of patients with significantly higher QoL ranking associated with MA (P= 0.002). Improvements in QoL occurred early within four weeks and weresustained. No statistically significant differences were observed in NSmeasurements, including weight (P = 0.29). Side effects of therapy wereminor and did not differ significantly across treatments. Conclusion: Megestrol acetate given at 480 mg/day is usefulpalliation in patients with endocrine-insensitive advanced cancer. It improvesappetite, mood and overall quality of life in these patients, although notthrough a direct effect on nutritional status. 1569-8041 15698041 Springer |
| shingle_title_1 | Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial |
| shingle_title_2 | Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial |
| shingle_title_3 | Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial |
| shingle_title_4 | Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial |
| sigel_instance_filter | dkfz geomar wilbert ipn albert fhp |
| source_archive | Springer Online Journal Archives 1860-2000 |
| timestamp | 2024-05-06T09:50:45.877Z |
| titel | Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial |
| titel_suche | Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial |
| topic | WW-YZ |
| uid | nat_lic_papers_NLM192898469 |